インシリコ臨床試験の世界市場レポート 2025年

インシリコ臨床試験市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.6％で56億4,000万米ドルに成長します。予測期間の成長は、医薬品開発プロセスの迅速化に対する需要の高まり、臨床試験における仮想患者集団の採用、デジタルツインテクノロジーの拡大、インシリコ試験に対する規制当局の受け入れ増加などに起因すると考えられます。予測期間における主な動向としては、より現実的な仮想患者モデルの開発、in silico試験における実世界のエビデンスの統合、分散化された患者中心の試験デザインの重視、デジタルバイオマーカーの使用の増加、仮想試験における個別化医療への注目の高まりなどが挙げられます。

感染症の流行が増加していることから、インシリコ臨床試験市場の今後の成長が期待されます。この増加には、都市化、過密化、気候変動、微生物の進化、旅行の増加などの要因が影響しています。インシリコ臨床試験は、計算モデルやシミュレーションを利用して感染症の治療開発を促進し、研究者が病気のメカニズムを分析し、薬剤の有効性を予測し、臨床試験デザインを最適化することで、最終的に患者の転帰を向上させ、公衆衛生イニシアチブを推進します。例えば、英国の公共部門情報サイトgov.ukによると、イングランドでは2022年に3,805件の新規HIV診断が記録され、2021年の3,118件から22％、2020年の3,026件から26％増加しました。このように、感染症の蔓延がインシリコ臨床試験市場を牽引しています。

インシリコ臨床試験市場の拡大には、臨床試験コストの削減ニーズがさらに拍車をかけています。臨床試験コストには、医療介入の安全性と有効性を評価するための試験の計画、実施、管理に関連する費用が含まれます。従来の臨床試験は長期的かつ高価であり、10～15年の期間と数十億の費用がかかります。インシリコ試験は、コンピューター・シミュレーションを使って介入を評価する、代替手段を提供するものです。例えば、Genetic Engineering and Biotechnology Newsによると、世界のバイオ医薬品企業上位20社の新薬開発コストは、臨床試験開発コストを含め、2022年の2億9,800万米ドルから2023年には約23億米ドルに上昇しました。インシリコ臨床試験へのシフトは、こうした費用の高騰を抑制する必要性が高まっていることが背景にあります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界インシリコ臨床試験PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のインシリコ臨床試験市場：成長率分析
• 世界のインシリコ臨床試験市場の実績：規模と成長, 2019-2024
• 世界のインシリコ臨床試験市場の予測：規模と成長, 2024-2029, 2034F
• 世界インシリコ臨床試験総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のインシリコ臨床試験市場フェーズ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェーズI
• フェーズII
• フェーズIII
• フェーズIV
• 世界のインシリコ臨床試験市場治療領域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 感染症
• 血液学
• 心臓病学
• 皮膚科
• 神経学
• 糖尿病
• その他の治療領域
• 世界のインシリコ臨床試験市場：業界別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 医療機器
• 製薬
• 世界のインシリコ臨床試験市場、フェーズIのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 安全性と投与量試験
• 薬物動態学および薬力学研究
• 世界のインシリコ臨床試験市場、フェーズ IIのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 有効性試験
• 用量反応研究
• 世界のインシリコ臨床試験市場、フェーズIIIのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 比較効果試験
• 大規模有効性研究
• 世界のインシリコ臨床試験市場、フェーズIVのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 市販後調査
• 長期安全性研究

第7章 地域別・国別分析

• 世界のインシリコ臨床試験市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のインシリコ臨床試験市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• インシリコ臨床試験市場：競合情勢
• インシリコ臨床試験市場：企業プロファイル
  • Dassault Systemes SE Overview, Products and Services, Strategy and Financial Analysis
  • Clarivate plc Overview, Products and Services, Strategy and Financial Analysis
  • Evotec A.G Overview, Products and Services, Strategy and Financial Analysis
  • Evidera Overview, Products and Services, Strategy and Financial Analysis
  • Certara Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abzena Limited
• Selvita
• Simulations Plus Inc.
• Insilico Medicine Inc.
• AnyLogic Company
• Biomax Informatics
• GNS Healthcare Inc.
• 4P-Pharma
• Nuventra Pharma Sciences
• Archimedes
• Novadiscovery Sas
• Rosa & Co.
• In Silico Biosciences
• Leadscope
• Biognos Ab

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• インシリコ臨床試験市場2029：新たな機会を提供する国
• インシリコ臨床試験市場2029：新たな機会を提供するセグメント
• インシリコ臨床試験市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

In silico clinical trials, also known as virtual clinical trials, involve computer simulations used to develop or evaluate the safety and efficacy of medicinal products, devices, or interventions. They serve as a method to assess the safety and effectiveness of medical devices and imaging systems.

The primary phases of in silico clinical trials include Phase I, Phase II, Phase III, and Phase IV. Phase I represents the initial evaluation of a drug or treatment on a small group of people, aiming to assess the safety and tolerability of new drugs in humans. These trials are conducted across various medical domains such as oncology, infectious disease, hematology, cardiology, dermatology, neurology, diabetes, and others. In silico clinical trials find applications in both the medical devices and pharmaceutical industries.

The in silico clinical trials research report is one of a series of new reports from The Business Research Company that provides in silico clinical trials market statistics, including the in silico clinical trials industry's global market size, regional shares, competitors with in silico clinical trials market share, detailed in silico clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the in silico clinical trials industry. This in silico clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The in silico clinical trials market size has grown strongly in recent years. It will grow from $3.51 billion in 2024 to $3.77 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increased availability of medical data, evolving regulatory frameworks for virtual trials, growth in computing power, rise in healthcare digitization, expansion of precision medicine initiatives

The in silico clinical trials market size is expected to see rapid growth in the next few years. It will grow to $5.64 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to growing demand for faster drug development processes, adoption of virtual patient populations in clinical trials, expansion of digital twin technologies, increase in regulatory acceptance of in silico trials. Major trends in the forecast period include development of more realistic virtual patient models, integration of real-world evidence in in silico trials, emphasis on decentralized and patient-centric trial designs, rise in the use of digital biomarkers, increased focus on personalized medicine in virtual trials.

The increasing prevalence of infectious diseases is expected to drive growth in the in silico clinical trials market in the future. This rise is influenced by factors such as urbanization, overcrowding, climate change, microbial evolution, and increased travel. In silico clinical trials utilize computational models and simulations to expedite the development of treatments for infectious diseases, allowing researchers to analyze disease mechanisms, predict drug efficacy, and optimize clinical trial designs, ultimately enhancing patient outcomes and advancing public health initiatives. For example, according to gov.uk, a UK-based public sector information website, England recorded 3,805 new HIV diagnoses in 2022, representing a 22% increase from the 3,118 cases reported in 2021 and a 26% rise from the 3,026 cases in 2020. Thus, the growing prevalence of infectious diseases is driving the in silico clinical trials market.

The expansion of the in silico clinical trials market is further fueled by the need to reduce clinical trial costs. Clinical trial costs encompass the expenses associated with planning, conducting, and managing trials to assess the safety and efficacy of medical interventions. Traditional trials are lengthy and expensive, taking 10-15 years and costing billions. In silico trials offer an alternative, using computer simulations to evaluate interventions. For instance, according to Genetic Engineering and Biotechnology News, the cost of developing a new drug among the top 20 global biopharma companies rose from $298 million in 2022 to approximately $2.3 billion in 2023, including clinical trial development costs. This shift towards in silico clinical trials is driven by the growing need to curb these escalating expenses.

A prominent trend in the in silico clinical trials market is the emergence of strategic partnerships. Major companies in the market are forming partnerships to enhance their market position. For instance, in March 2023, Premier Research, a US-based clinical research organization (CRO), partnered with InSilicoTrials to create efficient pathways for rare disease treatment approval. Similarly, 4P-Pharma, a France-based biotech company, collaborated with QuantHealth, an Israel-based AI company, to conduct patient-centric drug simulations, accelerating and de-risking drug development. These partnerships exemplify the industry trend of forming strategic alliances to strengthen market presence and facilitate advancements in in silico clinical trials.

Prominent players in the in silico clinical trials market are directing their focus towards cutting-edge technologies, specifically clinical trial platforms, to uphold their market positions. A clinical trial platform represents a specialized form of an adaptive, disease-centric, randomized clinical trial (RCT) formulated to assess multiple interventions concurrently against a consistent control group. As an illustration, in October 2023, Advarra, a US-based provider offering regulatory review solutions and clinical research technology for sites and sponsors, introduced Longboat v2.2. This new technological functionality aims to enhance the overall clinical trial experiences of stakeholders. Longboat, an established platform utilized in over 70 countries and by nearly 20,000 sites, now incorporates an online patient portal equipped with a comprehensive array of engagement tools. This includes a straightforward document exchange feature facilitating transparent collaboration among patients, sites, sponsors, or clinical research organizations (CROs), all while avoiding an additional technology burden.

In May 2023, Recursion, a US-based clinical-stage TechBio company, disclosed the acquisition of Cyclica and Valence for an undisclosed sum. These strategic acquisitions bring cutting-edge capabilities in digital chemistry, as well as machine learning and artificial intelligence from Cyclica and Valence. These capabilities are seamlessly integrated with Recursion's extensive automated wet-laboratories and supercomputing resources. This integration positions Recursion to deploy the most comprehensive, technology-enabled drug discovery solution within the biopharma industry. Cyclica, a biotechnology company based in Canada, and Valence, a Canadian deep learning research institute, collectively contribute to enhancing Recursion's capabilities in the pursuit of advancing drug discovery through innovative technologies.

Major companies operating in the in silico clinical trials market include Dassault Systemes SE, Clarivate plc, Evotec A.G, Evidera, Certara Inc., Abzena Limited, Selvita, Simulations Plus Inc., Insilico Medicine Inc., AnyLogic Company, Biomax Informatics, GNS Healthcare Inc., 4P-Pharma, Nuventra Pharma Sciences, Archimedes, Novadiscovery Sas, Rosa & Co., In Silico Biosciences, Leadscope, Biognos Ab, BioNova, Immunetrics Inc., InSilicoTrials, Physiomics plc, InhibOx, Entelos

North America was the largest region in the in silico clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the in silico clinical trials market report during the forecast period. The regions covered in the in silico clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the in silico clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The in silico clinical trials market includes revenues earned by entities by providing services such as data management, trial design, information compilation and site support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

In Silico Clinical Trials Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on in silico clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for in silico clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The in silico clinical trials market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Phase: Phase I; Phase II; Phase III; Phase IV
• 2) By Therapeutic Area: Oncology; Infectious Disease; Hematology; Cardiology; Dermatology; Neurology; Diabetes; Other Therapeutic Areas
• 3) By Industry: Medical Devices; Pharmaceutical
• Subsegments:
• 1) By Phase I: Safety And Dosage Trials; Pharmacokinetics And Pharmacodynamics Studies
• 2) By Phase II: Efficacy Trials; Dose-Response Studies
• 3) By Phase III: Comparative Effectiveness Trials; Large-Scale Efficacy Studies
• 4) By Phase IV: Post-Marketing Surveillance; Long-Term Safety Studies
• Companies Mentioned: Dassault Systemes SE; Clarivate plc; Evotec A.G; Evidera; Certara Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. In Silico Clinical Trials Market Characteristics

3. In Silico Clinical Trials Market Trends And Strategies

4. In Silico Clinical Trials Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global In Silico Clinical Trials Growth Analysis And Strategic Analysis Framework

• 5.1. Global In Silico Clinical Trials PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global In Silico Clinical Trials Market Growth Rate Analysis
• 5.4. Global In Silico Clinical Trials Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global In Silico Clinical Trials Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global In Silico Clinical Trials Total Addressable Market (TAM)

6. In Silico Clinical Trials Market Segmentation

• 6.1. Global In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phase I
• Phase II
• Phase III
• Phase IV
• 6.2. Global In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Infectious Disease
• Hematology
• Cardiology
• Dermatology
• Neurology
• Diabetes
• Other Therapeutic Areas
• 6.3. Global In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medical Devices
• Pharmaceutical
• 6.4. Global In Silico Clinical Trials Market, Sub-Segmentation Of Phase I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Safety And Dosage Trials
• Pharmacokinetics And Pharmacodynamics Studies
• 6.5. Global In Silico Clinical Trials Market, Sub-Segmentation Of Phase II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Efficacy Trials
• Dose-Response Studies
• 6.6. Global In Silico Clinical Trials Market, Sub-Segmentation Of Phase III, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Comparative Effectiveness Trials
• Large-Scale Efficacy Studies
• 6.7. Global In Silico Clinical Trials Market, Sub-Segmentation Of Phase IV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Post-Marketing Surveillance
• Long-Term Safety Studies

7. In Silico Clinical Trials Market Regional And Country Analysis

• 7.1. Global In Silico Clinical Trials Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global In Silico Clinical Trials Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific In Silico Clinical Trials Market

• 8.1. Asia-Pacific In Silico Clinical Trials Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China In Silico Clinical Trials Market

• 9.1. China In Silico Clinical Trials Market Overview
• 9.2. China In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India In Silico Clinical Trials Market

• 10.1. India In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan In Silico Clinical Trials Market

• 11.1. Japan In Silico Clinical Trials Market Overview
• 11.2. Japan In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia In Silico Clinical Trials Market

• 12.1. Australia In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia In Silico Clinical Trials Market

• 13.1. Indonesia In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea In Silico Clinical Trials Market

• 14.1. South Korea In Silico Clinical Trials Market Overview
• 14.2. South Korea In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe In Silico Clinical Trials Market

• 15.1. Western Europe In Silico Clinical Trials Market Overview
• 15.2. Western Europe In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK In Silico Clinical Trials Market

• 16.1. UK In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany In Silico Clinical Trials Market

• 17.1. Germany In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France In Silico Clinical Trials Market

• 18.1. France In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy In Silico Clinical Trials Market

• 19.1. Italy In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain In Silico Clinical Trials Market

• 20.1. Spain In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe In Silico Clinical Trials Market

• 21.1. Eastern Europe In Silico Clinical Trials Market Overview
• 21.2. Eastern Europe In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia In Silico Clinical Trials Market

• 22.1. Russia In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America In Silico Clinical Trials Market

• 23.1. North America In Silico Clinical Trials Market Overview
• 23.2. North America In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA In Silico Clinical Trials Market

• 24.1. USA In Silico Clinical Trials Market Overview
• 24.2. USA In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada In Silico Clinical Trials Market

• 25.1. Canada In Silico Clinical Trials Market Overview
• 25.2. Canada In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America In Silico Clinical Trials Market

• 26.1. South America In Silico Clinical Trials Market Overview
• 26.2. South America In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil In Silico Clinical Trials Market

• 27.1. Brazil In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East In Silico Clinical Trials Market

• 28.1. Middle East In Silico Clinical Trials Market Overview
• 28.2. Middle East In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa In Silico Clinical Trials Market

• 29.1. Africa In Silico Clinical Trials Market Overview
• 29.2. Africa In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. In Silico Clinical Trials Market Competitive Landscape And Company Profiles

• 30.1. In Silico Clinical Trials Market Competitive Landscape
• 30.2. In Silico Clinical Trials Market Company Profiles
  • 30.2.1. Dassault Systemes SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Clarivate plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Evotec A.G Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Evidera Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Certara Inc. Overview, Products and Services, Strategy and Financial Analysis

31. In Silico Clinical Trials Market Other Major And Innovative Companies

• 31.1. Abzena Limited
• 31.2. Selvita
• 31.3. Simulations Plus Inc.
• 31.4. Insilico Medicine Inc.
• 31.5. AnyLogic Company
• 31.6. Biomax Informatics
• 31.7. GNS Healthcare Inc.
• 31.8. 4P-Pharma
• 31.9. Nuventra Pharma Sciences
• 31.10. Archimedes
• 31.11. Novadiscovery Sas
• 31.12. Rosa & Co.
• 31.13. In Silico Biosciences
• 31.14. Leadscope
• 31.15. Biognos Ab

32. Global In Silico Clinical Trials Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The In Silico Clinical Trials Market

34. Recent Developments In The In Silico Clinical Trials Market

35. In Silico Clinical Trials Market High Potential Countries, Segments and Strategies

• 35.1 In Silico Clinical Trials Market In 2029 - Countries Offering Most New Opportunities
• 35.2 In Silico Clinical Trials Market In 2029 - Segments Offering Most New Opportunities
• 35.3 In Silico Clinical Trials Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer